X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11857) 11857
Newspaper Article (153) 153
Newsletter (38) 38
Magazine Article (17) 17
Book Chapter (5) 5
Book / eBook (4) 4
Reference (3) 3
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Publication (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8636) 8636
antibiotics, antineoplastic - administration & dosage (6265) 6265
female (5479) 5479
male (4978) 4978
animals (4601) 4601
doxorubicin - administration & dosage (3191) 3191
middle aged (3182) 3182
oncology (2951) 2951
adult (2628) 2628
antibiotics, antineoplastic - therapeutic use (2628) 2628
aged (2609) 2609
doxorubicin (2485) 2485
cancer (2478) 2478
mice (2473) 2473
chemotherapy (2423) 2423
pharmacology & pharmacy (2027) 2027
antibiotics, antineoplastic - pharmacology (1998) 1998
antibiotics, antineoplastic - adverse effects (1907) 1907
treatment outcome (1688) 1688
anthracyclines (1584) 1584
cell line, tumor (1425) 1425
antineoplastic combined chemotherapy protocols - therapeutic use (1383) 1383
rats (1348) 1348
antibiotics, antineoplastic - pharmacokinetics (1236) 1236
antibiotics (1134) 1134
doxorubicin - pharmacology (1109) 1109
therapy (1058) 1058
drug delivery systems (1056) 1056
breast neoplasms - drug therapy (1029) 1029
doxorubicin - therapeutic use (962) 962
antibiotics, antineoplastic - toxicity (954) 954
dose-response relationship, drug (907) 907
drugs (904) 904
tumors (891) 891
doxorubicin - pharmacokinetics (880) 880
neoplasms - drug therapy (868) 868
mitomycin - administration & dosage (857) 857
time factors (854) 854
antibiotics, antineoplastic - chemistry (848) 848
care and treatment (815) 815
nanoparticles (811) 811
analysis (801) 801
apoptosis (794) 794
doxorubicin - adverse effects (784) 784
adolescent (746) 746
research (744) 744
combined modality therapy (736) 736
liposomes (730) 730
aged, 80 and over (719) 719
mice, inbred balb c (712) 712
doxorubicin - chemistry (698) 698
drug administration schedule (697) 697
cell survival - drug effects (694) 694
follow-up studies (683) 683
medicine & public health (682) 682
antineoplastic agents - administration & dosage (674) 674
retrospective studies (659) 659
chemistry, multidisciplinary (657) 657
surgery (653) 653
toxicity (633) 633
adriamycin (620) 620
mice, nude (609) 609
health aspects (604) 604
apoptosis - drug effects (594) 594
breast cancer (589) 589
prospective studies (589) 589
doxorubicin - toxicity (579) 579
cells (577) 577
child (560) 560
drug therapy (559) 559
bleomycin - administration & dosage (558) 558
antineoplastic combined chemotherapy protocols - adverse effects (552) 552
epirubicin - administration & dosage (549) 549
cardiotoxicity (547) 547
pharmacokinetics (536) 536
doxorubicin - analogs & derivatives (526) 526
expression (521) 521
breast neoplasms - pathology (517) 517
in-vitro (517) 517
risk factors (498) 498
hematology (495) 495
dosage and administration (494) 494
disease models, animal (490) 490
vehicles (490) 490
drug-delivery (481) 481
drug carriers (479) 479
antineoplastic combined chemotherapy protocols - administration & dosage (469) 469
carcinoma (468) 468
antineoplastic agents - therapeutic use (462) 462
prognosis (434) 434
survival rate (432) 432
antineoplastic agents, phytogenic - administration & dosage (431) 431
biochemistry & molecular biology (431) 431
drug carriers - chemistry (430) 430
in-vivo (430) 430
tumor cells, cultured (429) 429
fluorouracil - administration & dosage (427) 427
survival analysis (426) 426
cytotoxicity (422) 422
rats, wistar (422) 422
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11249) 11249
Japanese (522) 522
Russian (231) 231
French (135) 135
German (125) 125
Chinese (119) 119
Italian (56) 56
Spanish (28) 28
Portuguese (17) 17
Polish (15) 15
Hungarian (14) 14
Czech (10) 10
Danish (10) 10
Lithuanian (7) 7
Ukrainian (6) 6
Norwegian (5) 5
Romanian (5) 5
Dutch (4) 4
Serbian (3) 3
Turkish (3) 3
Finnish (2) 2
Bulgarian (1) 1
Hebrew (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 1528-0020, 2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 4, pp. 397 - 407
Journal Article
Journal of controlled release, ISSN 0168-3659, 2016, Volume 229, pp. 154 - 162
...) that inarguably offers superior therapeutic efficacies compared to free drug administrations. Delivery of synergistic ratios of this drug pair led to greater than 90... 
Synergistic | Nanoparticles | Chemotherapy | Drug combinations | Liposomes | CATIONIC LIPOSOMES | TUMOR-CELLS | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | BREAST-CANCER | 5-FLUOROURACIL | CIRCULATION TIME | RANDOMIZED PHASE-III | ADVANCED GASTRIC-CANCER | PHARMACOLOGY & PHARMACY | EUROPEAN-ORGANIZATION | THERAPEUTIC ACTIVITY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Tryptophan - chemistry | Polyethylene Glycols - chemistry | Doxorubicin - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Antibiotics, Antineoplastic - chemistry | Female | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Cell Line | Antimetabolites, Antineoplastic - chemistry | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Animals | Antibiotics, Antineoplastic - therapeutic use | Tumor Burden - drug effects | Fluorouracil - chemistry | Cell Line, Tumor | Mice, Inbred BALB C | Fluorouracil - pharmacokinetics | Neoplasms - pathology | Drug Combinations | Drugs | Anthracyclines | Drug delivery systems | Sulfates | Vehicles | Cancer | School facilities | Biomedical engineering | Education parks | Index Medicus | synergistic | nanoparticles | liposomes | chemotherapy
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2000, Volume 18, Issue 4, pp. 854 - 854
Purpose: To evaluate the results of etoposide, cisplatin/etoposide, methotrexate, and actinomycin D (EP/EMA) chemotherapy in patients with gestational... 
MANAGEMENT | ONCOLOGY | DISEASE | CHORIOCARCINOMA | EXPERIENCE | HIGH-DOSE CHEMOTHERAPY | REMISSION | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Antineoplastic Agents - administration & dosage | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents - adverse effects | Dactinomycin - adverse effects | Chorionic Gonadotropin - blood | Adult | Female | Antineoplastic Agents, Phytogenic - adverse effects | Etoposide - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Dactinomycin - administration & dosage | Remission Induction | Antibiotics, Antineoplastic - administration & dosage | Pregnancy | Methotrexate - adverse effects | Uterine Neoplasms - surgery | Trophoblastic Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Trophoblastic Neoplasms - surgery | Trophoblastic Neoplasms - secondary | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Placenta - pathology | Uterine Neoplasms - drug therapy | Cisplatin - adverse effects | Methotrexate - administration & dosage | Antineoplastic Agents, Alkylating - adverse effects | Cohort Studies
Journal Article
American journal of hematology, ISSN 0361-8609, 2013, Volume 88, Issue 11, pp. 961 - 966
Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin,... 
PHASE-III TRIAL | SOUTHWEST-ONCOLOGY-GROUP | DOSE CYTOSINE-ARABINOSIDE | GROUP-B | ARA-C | DAUNORUBICIN | HEMATOLOGY | CANCER | CHEMOTHERAPY | MODULATION | INDUCTION TREATMENT | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Follow-Up Studies | Nausea - chemically induced | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Young Adult | Arabinonucleosides - administration & dosage | Idarubicin - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Idarubicin - administration & dosage | Adenine Nucleotides - administration & dosage | Idarubicin - therapeutic use | Drug Eruptions - etiology | Adenine Nucleotides - therapeutic use | Arabinonucleosides - adverse effects | Remission Induction | Arabinonucleosides - therapeutic use | Cytarabine - administration & dosage | Adenine Nucleotides - adverse effects | Induction Chemotherapy - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Pilot Projects | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Consolidation Chemotherapy - adverse effects | Anthracyclines | Index Medicus | AML | idarubicin | cytarabine | frontline therapy | clofarabine
Journal Article
Biomaterials, ISSN 0142-9612, 2008, Volume 29, Issue 29, pp. 4012 - 4021
Abstract There is significant interest in recent years in developing magnetic nanoparticles (MNPs) having multifunctional characteristics with complimentary... 
Advanced Basic Science | Dentistry | Tumor | Iron oxide | Anticancer agents | Anti-proliferative effects | Imaging | VITRO | HYPERTHERMIA | anti-proliferative effects | MATERIALS SCIENCE, BIOMATERIALS | CONTRAST AGENTS | ENGINEERING, BIOMEDICAL | SURFACE MODIFICATION | ADRIAMYCIN CARDIOTOXICITY | imaging | CHEMOTHERAPY | anticancer agents | iron oxide | SUPERPARAMAGNETIC NANOPARTICLES | POLY(ETHYLENE GLYCOL) | CANCER-TREATMENT | tumor | IN-VIVO | Paclitaxel - metabolism | Nanoparticles - chemistry | Magnetic Resonance Imaging - methods | Doxorubicin - chemistry | Magnetics | Drug Carriers - chemistry | Drug Delivery Systems | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Antibiotics, Antineoplastic - chemistry | Antineoplastic Agents, Phytogenic - metabolism | Doxorubicin - metabolism | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Carriers - metabolism | Antineoplastic Agents, Phytogenic - chemistry | Materials Testing | Antibiotics, Antineoplastic - administration & dosage | Particle Size | Animals | Magnetic Resonance Imaging - instrumentation | Mice, Nude | Mice | Nanoparticles - administration & dosage | Antibiotics, Antineoplastic - metabolism | Drugs | Nanoparticles | Drug delivery systems | Magnetic resonance imaging | Nanotechnology | Vehicles | Iron-oxide
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2012, Volume 8, Issue 1, pp. 81 - 92
Abstract The present study demonstrates the applicability of a novel strategy that employs targeted delivery of combined treatment against tumor... 
Internal Medicine | Tumor neovasculature | Combretastatin A4 | Combination therapy | Targeted delivery | Doxorubicin | MEDICINE, RESEARCH & EXPERIMENTAL | DIBLOCK COPOLYMERS | CELLS | GENE DELIVERY | DRUG-DELIVERY | NANOSCIENCE & NANOTECHNOLOGY | MULTIFUNCTIONAL POLYMERIC MICELLES | METRONOMIC CHEMOTHERAPY | PACLITAXEL | RGD PEPTIDE | ANGIOGENESIS INHIBITORS | INTRACELLULAR DELIVERY | Human Umbilical Vein Endothelial Cells | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Stilbenes - administration & dosage | Stilbenes - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - chemistry | Humans | Polyethylene Glycols - chemistry | Doxorubicin - chemistry | Stilbenes - chemistry | Polyethylene Glycols - therapeutic use | Drug Carriers - chemistry | Peptides, Cyclic - chemistry | Drug Delivery Systems | Antineoplastic Agents, Phytogenic - administration & dosage | Antibiotics, Antineoplastic - chemistry | Melanoma, Experimental | Micelles | Antineoplastic Agents, Phytogenic - therapeutic use | Lactates - chemistry | Doxorubicin - administration & dosage | Mice, Inbred C57BL | Antineoplastic Agents, Phytogenic - chemistry | Lactates - therapeutic use | Antibiotics, Antineoplastic - administration & dosage | Animals | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Peptides, Cyclic - therapeutic use | Cell Proliferation - drug effects | Mice | Anthracyclines | Dosage and administration | Tumors | Integrins
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9707, pp. 2055 - 2063
Summary Background Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of... 
Internal Medicine | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | THERAPY | CYCLOPHOSPHAMIDE | METHOTREXATE | ANTAGONISM | CARCINOMA | FLUOROURACIL CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Lymph Nodes - pathology | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Alkylating - administration & dosage | Tamoxifen - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Receptors, Progesterone - analysis | Fluorouracil - administration & dosage | Postmenopause | Adult | Female | Chemotherapy, Adjuvant | Doxorubicin - administration & dosage | Antineoplastic Agents, Hormonal - administration & dosage | Lymphatic Metastasis | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Adenocarcinoma - mortality | Adjuvant treatment | Breast cancer | Dosage and administration | Research | Drug therapy | Tamoxifen | Health aspects | Cancer | Heart failure | Chemotherapy | Womens health | Mortality | Clinical trials | Mammography | Radiation therapy | Cancer therapies | Tumors | Toxicity | Leukemia | Congestive heart failure | Doxorubicin | Evidence-based medicine | Subgroups | Rank tests | Randomization | Motivation | Registration | Mastectomy | Thromboembolism | Neutropenia | Review boards | Regression analysis | Patients | Survival | Post-menopause | Stomatitis | Cyclophosphamide | Anthracycline | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 7, pp. 860 - 867
Journal Article